CinCor Pharma (CINC) Announces Proposed 6M Share Offering

CinCor Pharma, Inc. (Nasdaq: CINC) today announced that it has launched an underwritten public offering of 6,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission. CinCor may, in lieu of common stock, offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in the underwritten public offering. CinCor also intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. All of the securities to be sold in the proposed offering will be offered by CinCor.

Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies and Piper Sandler & Co. are acting as joint book-running managers for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms of the proposed offering.

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) but has not yet become effective. The securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective.

The proposed offering will be made only by means of a prospectus. Copies of the registration statement and the preliminary prospectus relating to the proposed offering may be obtained, when available, on the SEC’s website at http://www.sec.gov or may be obtained by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected]; Morgan Stanley & Co. LLC by mail at Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at (866) 718-1649 or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; and Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• GXO Logistics, Inc. (GXO) Prices $1.1B Notes Offering
• IBM (IBM) to Acquire HashiCorp (HCP) for $35/sh Cash or $6.4B
• Masonite (DOOR) Shareholders Approve Transaction with Owens Corning (OC)